Alessandro Manzoni Hospital

At Alessandro Manzoni Hospital in Lecco, the cardiovascular diseases portfolio focuses on preventing serious clot-related events in people with atrial fibrillation and after stroke or high-risk transient ischemic attack. These studies are designed to compare treatment effectiveness and improve protection against future ischemic complications.

• Reducing the risk of cardioembolic events in atrial fibrillation
• Evaluating prevention of recurrent ischemic stroke after a recent cerebrovascular event
• Assessing clinical benefit of newer anticoagulation approaches versus established care

This area reflects a strong interest in refining stroke prevention and improving everyday management of patients at risk of major vascular events.

The site’s neoplasms research is especially active in endometrial cancer and ovarian cancer, including advanced, recurrent, and platinum-sensitive disease. The trials explore maintenance strategies and treatment combinations aimed at extending disease control and improving outcomes for women with hard-to-treat gynecologic cancers.

• Testing maintenance treatment options in advanced or recurrent endometrial cancer
• Confirming the value of targeted therapy for HRD-positive ovarian cancer
• Comparing combination approaches to delay progression in recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

Research in this field at Alessandro Manzoni Hospital is centered on improving long-term control with targeted therapy and maintenance treatment after initial chemotherapy.

Another oncology theme involves breast cancer, with studies focused on ER-positive, HER2-negative disease and the risk of relapse. The goal is to evaluate whether a new endocrine treatment approach can better delay distant spread or death in patients with early molecular signs of recurrence.

• Studying treatment strategies for ctDNA-positive early breast cancer
• Comparing a novel endocrine option with standard hormonal therapy
• Improving outcomes for patients at higher risk of distant metastasis

This research highlights the growing role of molecular monitoring in guiding more personalized cancer care.

The site also contributes to pathological conditions, signs and symptoms research through studies in intracerebral hemorrhage and myocarditis. In the neurological setting, the focus is on whether a treatment can improve survival and support better early outcomes after a bleeding event in the brain.

• Evaluating treatment effectiveness in hyperacute spontaneous intracerebral hemorrhage
• Assessing whether early intervention can improve short-term outcomes after ICH
• Exploring supportive care approaches for serious acute inflammatory conditions such as myocarditis

These studies aim to strengthen acute care for patients with urgent, high-risk conditions where rapid treatment may influence recovery.

Within the virus diseases area, the hospital is involved in research on influenza, particularly in adults aged 65 and older. The trials are designed to evaluate how well vaccination helps prevent confirmed influenza illness and to support better protection in an older population.

• Measuring protection against influenza A and B in older adults
• Comparing vaccine effectiveness for seasonal influenza prevention
• Supporting public health efforts to reduce flu-related illness in senior patients

This work reflects a practical focus on preventive medicine and reducing the burden of seasonal viral infection.

The research portfolio also includes studies on acute myocarditis, examining ways to improve heart function in patients with inflammatory heart disease. These trials are intended to test whether a treatment approach can better preserve or restore cardiac performance.

• Assessing recovery of left ventricular function in myocarditis
• Evaluating supportive treatment for patients with reduced heart pumping ability
• Improving clinical management of inflammatory cardiac disease

This area connects cardiology with efforts to improve functional recovery and day-to-day outcomes in patients affected by heart inflammation.